image
ICU Medical, Inc. ICUI
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
Watchlist
$ 133.07
1.19 %
$ 3.28 B
Market Cap
-34.8
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ICUI stock under the worst case scenario is HIDDEN Compared to the current market price of 133 USD, ICU Medical, Inc. is HIDDEN

ICUI Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ICUI stock under the base case scenario is HIDDEN Compared to the current market price of 133 USD, ICU Medical, Inc. is HIDDEN

ICUI Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ICUI stock under the best case scenario is HIDDEN Compared to the current market price of 133 USD, ICU Medical, Inc. is HIDDEN

ICUI Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart ICUI

image
1M -6%
6M -24%
1Y 17%
3Y -22%
5Y -38%
All
$175.0$175.0$170.0$170.0$165.0$165.0$160.0$160.0$155.0$155.0$150.0$150.0$145.0$145.0$140.0$140.0$135.0$135.0$130.0$130.0$125.0$125.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
2.38 B REVENUE
5.44%
Growth Rates
1Year 5.44%
3Years 21.86%
5Years 13.47%
7Years 9.13%
10Years 22.65%
43 M OPERATING INCOME
88.23%
Growth Rates
1Year 88.23%
3Years -6.39%
5Years -7.43%
7Years 25.30%
10Years 0.96%
-118 M NET INCOME
-296.86%
Growth Rates
1Year -296.86%
3Years -28.89%
5Years -16.70%
7Years -15.33%
10Years -18.52%
204 M OPERATING CASH FLOW
22.76%
Growth Rates
1Year 22.76%
3Years -8.64%
5Years 14.89%
7Years 4.06%
10Years 12.90%
-89 M INVESTING CASH FLOW
-1.15%
Growth Rates
1Year -1.15%
3Years 0.64%
5Years 11.82%
7Years 14.52%
10Years -15.13%
-55.8 M FINANCING CASH FLOW
-55.09%
Growth Rates
1Year -55.09%
3Years -49.00%
5Years -38.61%
7Years -3.34%
10Years -14.53%
605 M REVENUE
-3.99%
Growth Rates
1Year 5.44%
3Years 21.86%
5Years 13.47%
7Years 9.13%
10Years 22.65%
12.9 M OPERATING INCOME
-65.81%
Growth Rates
1Year 88.23%
3Years -6.39%
5Years -7.43%
7Years 25.30%
10Years 0.96%
-15.5 M NET INCOME
35.05%
Growth Rates
1Year -296.86%
3Years -28.89%
5Years -16.70%
7Years -15.33%
10Years -18.52%
51.3 M OPERATING CASH FLOW
27.70%
Growth Rates
1Year 22.76%
3Years -8.64%
5Years 14.89%
7Years 4.06%
10Years 12.90%
-16.8 M INVESTING CASH FLOW
36.67%
Growth Rates
1Year -1.15%
3Years 0.64%
5Years 11.82%
7Years 14.52%
10Years -15.13%
-56.3 M FINANCING CASH FLOW
-587.78%
Growth Rates
1Year -55.09%
3Years -49.00%
5Years -38.61%
7Years -3.34%
10Years -14.53%
Balance Sheet ICU Medical, Inc.
image
Current Assets 1.44 B
Cash & Short-Term Investments 309 M
Receivables 203 M
Other Current Assets 931 M
Non-Current Assets 2.76 B
Long-Term Investments 3.04 M
PP&E 499 M
Other Non-Current Assets 2.26 B
7.34 %4.82 %22.14 %11.88 %53.75 %Total Assets$4.2b
Current Liabilities 556 M
Accounts Payable 148 M
Short-Term Debt 66.7 M
Other Current Liabilities 341 M
Non-Current Liabilities 1.68 B
Long-Term Debt 1.57 B
Other Non-Current Liabilities 108 M
6.61 %2.98 %15.25 %70.35 %4.80 %Total Liabilities$2.2b
EFFICIENCY
Earnings Waterfall ICU Medical, Inc.
image
Revenue 2.38 B
Cost Of Revenue 1.56 B
Gross Profit 825 M
Operating Expenses 782 M
Operating Income 43 M
Other Expenses 161 M
Net Income -118 M
3b3b2b2b2b2b1b1b500m500m00(500m)(500m)2b(2b)825m(782m)43m(161m)(118m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
34.62% GROSS MARGIN
34.62%
Averages
1Year 34.62%
3Years 32.66%
5Years 34.33%
7Years 35.66%
10Years 38.86%
1.80% OPERATING MARGIN
1.80%
Averages
1Year 1.80%
3Years 0.81%
5Years 1.94%
7Years 2.32%
10Years 5.70%
-4.94% NET MARGIN
-4.94%
Averages
1Year -4.94%
3Years -3.17%
5Years 1.03%
7Years 2.17%
10Years 5.03%
-5.99% ROE
-5.99%
Averages
1Year -5.99%
3Years -3.65%
5Years 0.25%
7Years 1.55%
10Years 3.39%
-2.80% ROA
-2.80%
Averages
1Year -2.80%
3Years -1.71%
5Years 1.06%
7Years 1.87%
10Years 3.38%
2.06% ROIC
2.06%
Averages
1Year 2.06%
3Years 0.71%
5Years 1.42%
7Years 1.86%
10Years 2.83%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ICU Medical, Inc.
image
200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -118 M
Depreciation & Amortization 220 M
Capital Expenditures -79.4 M
Stock-Based Compensation 46.9 M
Change in Working Capital 0
Others 57.9 M
Free Cash Flow 125 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ICU Medical, Inc.
image
Wall Street analysts predict an average 1-year price target for ICUI of $153 , with forecasts ranging from a low of $97 to a high of $198 .
ICUI Lowest Price Target Wall Street Target
97 USD -27.11%
ICUI Average Price Target Wall Street Target
153 USD 15.16%
ICUI Highest Price Target Wall Street Target
198 USD 48.79%
Price
Max Price Target
Min Price Target
Average Price Target
2002001801801601601401401201201001008080Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership ICU Medical, Inc.
image
Sold
0-3 MONTHS
7.7 M USD 5
3-6 MONTHS
213 K USD 1
6-9 MONTHS
8.45 M USD 4
9-12 MONTHS
4.54 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc. - ICUI NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc.("ICU" or the "Company") (NASDAQ:ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc. - ICUI NEW YORK CITY, NY / ACCESS Newswire / May 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc.("ICU" or the "Company") (NASDAQ:ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc. - ICUI NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  ICU Medical, Inc. (“ICU” or the “Company”) (NASDAQ: ICUI).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc. - ICUI NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc.("ICU" or the "Company") (NASDAQ:ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc. - ICUI NEW YORK , May 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc. ("ICU" or the "Company") (NASDAQ: ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc. - ICUI NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc.("ICU" or the "Company") (NASDAQ:ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 4 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc. - ICUI NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc.("ICU" or the "Company") (NASDAQ:ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc. - ICUI NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc.("ICU" or the "Company") (NASDAQ:ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ICU Medical, Inc. – ICUI NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc. (“ICU” or the “Company”) (NASDAQ: ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc. - ICUI NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc. ("ICU" or the "Company") (NASDAQ: ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 1 month ago
ICU Medical, Inc. (ICUI) Q1 2025 Earnings Call Transcript ICU Medical, Inc. (NASDAQ:ICUI ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants John Mills – ICR, IR Vivek Jain – Chief Executive Officer and Chairman Brian Bonnell – Chief Financial Officer Conference Call Participants Jayson Bedford – Raymond James Brett Fishbin – KeyBanc Capital Markets Larry Solow – CJS Securities Michael Toomey – Jefferies Operator Good day, and welcome to the ICU Medical, Inc. First Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note, today's event is being recorded. seekingalpha.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc. - ICUI NEW YORK CITY, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc.("ICU" or the "Company") (NASDAQ:ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 month ago
8. Profile Summary

ICU Medical, Inc. ICUI

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 3.28 B
Dividend Yield 0.00%
Description ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
Contact 951 Calle Amanecer, San Clemente, CA, 92673 https://www.icumed.com
IPO Date March 31, 1992
Employees 15000
Officers Mr. Daniel Woolson President Mr. Christian B. Voigtlander Chief Operating Officer Ms. Virginia Ruth Sanzone Corporate Vice President, General Counsel, Secretary & Compliance Officer Olivia Barrall Vice President of Human Resources Mr. Brian Michael Bonnell Chief Financial Officer & Treasurer Ben Sousa Chief Information Officer Mr. Vivek Jain Chief Executive Officer & Chairman of the Board